New report from global cancer experts outlines barriers to cancer care and recent achievements in the three countries with more than half of the world’s deaths from cancer.
The Lancet Oncology
The Lancet Oncology today [Friday 11 April] publishes a major new Commission examining the challenges to effective cancer control in China, India, and Russia – which together experience 46% of all new cancers worldwide, and account for more than half (52%) of all cancer deaths globally. The Commission was led by Professor Paul Goss, of Harvard Medical School and Massachusetts General Hospital Cancer Center, USA, in collaboration with over 40 leading cancer experts from the regions studied, and across the world.
At the same time, the journal also publishes a three part Series on cancer burden and health systems in India, coordinated by Professor Richard Sullivan, of King’s College London, UK, and with contributions from many of India’s leading cancer experts, including Professor C S Pramesh, of the Tata Memorial Centre, Mumbai, India, and Professor Mohandas Mallath, of the Tata Medical Center, Kolkata, India.
Mojiang paramyxovirus (MojV) is a newly discovered dreadful virus in Yunnan Province of China. It has genetic similarity to henipaviruses and other members of family Paramyxoviridae. Its potential reservoir is rodents (rats).
Over the last 20 years, China has more than halved its tuberculosis (TB) prevalence, with rates falling from 170 to 59 per 100 000 population. This unrivalled success has been driven by a massive scale-up of the directly observed, short-course (DOTS) strategy, from half the population in the 1990s to the entire country after 2000, according to findings from a 20-year-long analysis of national survey data, published in The Lancet.
“One of the key global TB targets set by the Stop TB Partnership aims to reduce tuberculosis prevalence by 50% between 1990 and 2015. This study in China is the first to show the feasibility of achieving such a target, and China achieved this 5 years earlier than the target date”, says study leader Dr Yu Wang from the Chinese Center for Disease Control and Prevention in Beijing, China.
Nanoparticles capable of delivering drugs to specifically targeted cancer cells have been created by a group of researchers from China.
The multifunctional ‘smart’ gold nanoshells could lead to more effective cancer treatments by overcoming a major limitation of modern chemotherapy techniques—the ability to target cancer cells specifically and leave healthy cells untouched.
Scientists from China report in The Lancet on the world’s first confirmed case of human infection with a new avian influenza A H10N8 virus in a 73-year-old woman who died from the infection.
Tests on tracheal swab samples established that the virus was a new genetic reassortment avian-origin H10N8 virus (JX346). Whole genome sequencing indicated that all the genes of the virus were of avian origin, with six internal genes derived from avian H9N2 viruses that are circulating in poultry in China.
“A genetic analysis of the H10N8 virus shows a virus that is distinct from previously reported H10N8 viruses having evolved some genetic characteristics that may allow it to replicate efficiently in humans. Notably, H9N2 virus provided the internal genes not only for the H10N8 virus, but also for H7N9 and H5N1 viruses”, explains author Dr Yuelong Shu from the Chinese Center for Disease Control and Prevention, Beijing.* Read more…